Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Cardiol Therapeutics Inc Class A (CRDL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: CRDL (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit -54.86% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 79.90M USD | Price to earnings Ratio - | 1Y Target Price 8.67 |
Price to earnings Ratio - | 1Y Target Price 8.67 | ||
Volume (30-day avg) 253714 | Beta 0.57 | 52 Weeks Range 0.88 - 3.12 | Updated Date 04/1/2025 |
52 Weeks Range 0.88 - 3.12 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.38 |
Earnings Date
Report Date 2025-03-31 | When After Market | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -79.07% | Return on Equity (TTM) -159.53% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 66794809 | Price to Sales(TTM) 1069.35 |
Enterprise Value 66794809 | Price to Sales(TTM) 1069.35 | ||
Enterprise Value to Revenue 178.81 | Enterprise Value to EBITDA 0.3 | Shares Outstanding 81603400 | Shares Floating 77722363 |
Shares Outstanding 81603400 | Shares Floating 77722363 | ||
Percent Insiders 4 | Percent Institutions 12.19 |
Analyst Ratings
Rating 4.2 | Target Price 8.67 | Buy 4 | Strong Buy 1 |
Buy 4 | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Cardiol Therapeutics Inc Class A
Company Overview
History and Background
Cardiol Therapeutics Inc. is a biotechnology company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. Founded in 2016, it's focused on developing pharmaceutical cannabidiol (CBD) and other anti-inflammatory therapies for cardiovascular disease. It has gone through several clinical trials.
Core Business Areas
- Pharmaceutical Cannabidiol (CBD) Program: Development of pharmaceutical cannabidiol formulations for the treatment of cardiovascular diseases, focusing on reducing inflammation and fibrosis in the heart.
- Cardiometabolic Program: Researching and developing other anti-inflammatory therapies for cardiovascular disease, potentially including novel compounds or drug combinations.
Leadership and Structure
CEO: David Elsley. The structure is that of a clinical stage pharmaceutical development company with focus on research, clinical trials and regulatory approval
Top Products and Market Share
Key Offerings
- CardiolRx: A pharmaceutical cannabidiol formulation designed for cardiovascular indications. It is currently in clinical development for acute myocarditis and recurrent pericarditis. Market share is currently 0, as it is not yet approved. Key competitors will be existing treatments for those conditions, such as NSAIDs, colchicine, corticosteroids and other immune modulating therapies.
- Other cardiometabolic programs: These are not yet defined products. Competitors would depend on which programs enter clinical trials.
Market Dynamics
Industry Overview
The cardiovascular therapeutics market is a large and growing market, driven by an aging population, increasing prevalence of heart disease, and advances in medical technology. Inflammation and fibrosis are increasingly recognized as key drivers of cardiovascular disease.
Positioning
Cardiol Therapeutics is positioning itself as a leader in the development of anti-inflammatory therapies for cardiovascular disease, specifically targeting CBD as a novel therapeutic approach. Their competitive advantage lies in their focus on cardiovascular indications and their proprietary formulations of CBD.
Total Addressable Market (TAM)
The global cardiovascular disease market size was valued at USD 175.87 billion in 2022 and is projected to grow from USD 186.39 billion in 2023 to USD 299.28 billion by 2030. Cardiol is focused on niche segments, but this is still a significant market opportunity.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approach (CBD)
- Focus on cardiovascular indications
- Proprietary formulations
- Experienced management team
Weaknesses
- Clinical stage company with no approved products
- Reliance on clinical trial success
- Relatively small market capitalization
- Heavy cash burn without revenue
Opportunities
- Successful clinical trial results
- Regulatory approval of CardiolRx
- Partnerships with larger pharmaceutical companies
- Expansion into new cardiovascular indications
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Changes in the regulatory landscape for CBD
Competitors and Market Share
Key Competitors
- JNJ
- PFE
- MRK
- BMY
- GILD
Competitive Landscape
Cardiol Therapeutics is a small player in a market dominated by large pharmaceutical companies. They are trying to differentiate themselves with a CBD-based therapy. They lack the marketing, distribution, and financial resources of their larger competitors.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is measured by advancing drug programs through clinical development, not by revenue.
Future Projections: Future growth is dependent on positive clinical trial outcomes and regulatory approvals for CardiolRx.
Recent Initiatives: Focus is primarily on advancing clinical trials for CardiolRx in myocarditis and pericarditis.
Summary
Cardiol Therapeutics is a high-risk, high-reward clinical-stage company focused on a novel therapeutic approach using CBD for cardiovascular diseases. Its success is heavily reliant on positive clinical trial outcomes and regulatory approval. The company needs to manage its cash flow carefully and potentially seek partnerships to offset the high costs of clinical development. There are opportunities to be capitalized, but there are threats to be wary of.
Similar Companies
- JAZZ
- GWPH
- ACHV
Sources and Disclaimers
Data Sources:
- Company filings
- Industry reports
- Analyst estimates
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. The data provided is based on available information and may be subject to change. Investments in clinical-stage pharmaceutical companies are highly speculative and involve substantial risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cardiol Therapeutics Inc Class A
Exchange NASDAQ | Headquaters Oakville, ON, Canada | ||
IPO Launch date 2019-01-15 | President, CEO & Director Mr. David G. Elsley MBA | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees - | Website https://www.cardiolrx.com |
Full time employees - | Website https://www.cardiolrx.com | ||
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.